Login to Your Account

GSK Pays Affiris $28M Up Front in Alzheimer's Vaccine Deal

By Catherine Hollingsworth

Monday, October 27, 2008
GlaxoSmithKline Biologicals SA, of Rixensart, Belgium, and Affiris GmbH entered a collaboration agreement granting GSK exclusive rights to Affiris's Alzheimer's disease vaccine programs targeting the beta-amyloid pathway. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription